Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 2:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 65 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Albuminuria Clear all
Not yet recruiting Not applicable Interventional

Optimizing Referral Pathways for Patients With Hematuria and Moderate-Severe Proteinuria

NCT07431931
View directory record Official record
Conditions
Referral and Consultation, Glomerulonephritis, Hematuria, Proteinuria, Kidney Disease
Interventions
Electronic Health Record alert
Other
Lead sponsor
Geisinger Clinic
Other
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Jul 21, 2026, 2:18 PM EDT
Recruiting Phase 2 Interventional

Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin

NCT07175051
View directory record Official record
Conditions
Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0), Albuminuria
Interventions
Empagliflozin (oral)
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Jul 21, 2026, 2:18 PM EDT
Completed Not applicable Interventional

Facilitating Improvements in Kidney Health Using a Smartphone App Counseling Program in Patients With Diabetes

NCT03015480
View directory record Official record
Conditions
Chronic Kidney Disease, Diabetes Mellitus, Albuminuria
Interventions
Remote counseling
Behavioral
Lead sponsor
Geisinger Clinic
Other
Eligibility
21 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Danville, Pennsylvania • Wilkes-Barre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 28, 2019 · Synced Jul 21, 2026, 2:18 PM EDT
Completed Not applicable Interventional

Lowering Salt Intake in Chronic Kidney Disease: A Pilot Randomized Crossover Trial

NCT00974636
View directory record Official record
Conditions
Kidney Disease
Interventions
Low Salt Diet, Usual Salt Diet
Dietary Supplement
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 85 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 4, 2015 · Synced Jul 21, 2026, 2:18 PM EDT
Recruiting Phase 2 Interventional

The EFfect of FinErenone in Kidney TransplantiOn Recipients: The EFFEKTOR Study

NCT06059664
View directory record Official record
Conditions
Kidney Transplant; Complications
Interventions
Finerenone Oral Tablet, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Jul 21, 2026, 2:18 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE)

NCT04752293
View directory record Official record
Conditions
Hypertension, Left Ventricular Hypertrophy, Left Ventricular Dysfunction, Left Atrial Dilatation, Left Ventricular Diastolic Dysfunction, Kidney Diseases, Kidney Injury, Kidney Dysfunction, Sodium Urine High, Blood Pressure Disorders, Uric Acid Retention, Angiotensin Hypertension, Autonomic Dysfunction, Autonomic Imbalance, Pediatric Kidney Disease, Pediatric Obesity, Proteinuria, Albuminuria
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
7 Years to 18 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Jul 21, 2026, 2:18 PM EDT
Completed Not applicable Interventional Results available

Vitamin D and Omega-3 Trial to Prevent and Treat Diabetic Kidney Disease

NCT01684722
View directory record Official record
Conditions
Diabetes
Interventions
Vitamin D, Omega-3 fatty acids (fish oil), Vitamin D placebo, Fish oil placebo
Dietary Supplement · Drug
Lead sponsor
University of Washington
Other
Eligibility
50 Years and older
Enrollment
1,312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 20, 2022 · Synced Jul 21, 2026, 2:18 PM EDT
Completed Not applicable Interventional

Aldosterone and Vascular Disease in Diabetes Mellitus

NCT00214825
View directory record Official record
Conditions
Diabetes Mellitus, Endothelial Dysfunction, Albuminuria
Interventions
eplerenone, Hydrochlorothiazide
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
21 Years to 64 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 2, 2008 · Synced Jul 21, 2026, 2:18 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria

NCT02010242
View directory record Official record
Conditions
Type 2 Diabetes Mellitus With Diabetic Nephropathy
Interventions
GKT137831, Placebo
Drug
Lead sponsor
Calliditas Therapeutics AB
Industry
Eligibility
18 Years to 80 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
20
States / cities
Tucson, Arizona • Orange, California • Coral Gables, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Jul 21, 2026, 2:18 PM EDT
Completed Phase 3 Interventional Results available

MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin

NCT01792518
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, Linagliptin 5mg
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
15
States / cities
Birmingham, Alabama • Long Beach, California • North Hollywood, California + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2017 · Synced Jul 21, 2026, 2:18 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

The Effect of LY333531 on Protein in the Urine in Patients With Type 2 Diabetes

NCT00044148
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
LY333531
Drug
Lead sponsor
Chromaderm, Inc.
Industry
Eligibility
30 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2004
U.S. locations
15
States / cities
La Jolla, California • Walnut Creek, California • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Jul 21, 2026, 2:18 PM EDT
Completed Not applicable Interventional

Improving Albuminuria Screening Compliance Using a Smartphone Urinalysis Kit

NCT03470701
View directory record Official record
Conditions
Albuminuria, Chronic Kidney Diseases, Cardiovascular Diseases, Hypertension
Interventions
Mailed Urinalysis Smartphone Kit
Other
Lead sponsor
Geisinger Clinic
Other
Eligibility
18 Years and older
Enrollment
999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 23, 2018 · Synced Jul 21, 2026, 2:18 PM EDT
Completed Phase 2 Interventional

Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor

NCT01356849
View directory record Official record
Conditions
Chronic Kidney Disease, Diabetic Nephropathy
Interventions
Atrasentan, Placebo
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
59
States / cities
Pell City, Alabama • Tempe, Arizona • Azusa, California + 48 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2013 · Synced Jul 21, 2026, 2:18 PM EDT
Terminated Phase 4 Interventional

Triple Blockade of the Renin Angiotensin Aldosterone System in Diabetic (Type 1&2) Proteinuric Patients

NCT00961207
View directory record Official record
Conditions
Microalbuminuria, Macroalbuminuric Diabetic Nephropathy, Diabetes, Proteinuria, Albuminuria
Interventions
Aliskiren
Drug
Lead sponsor
Cook County Health
Government
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 27, 2013 · Synced Jul 21, 2026, 2:18 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

World Trade Center Kidney-Link

NCT03234530
View directory record Official record
Conditions
Chronic Kidney Diseases, Obstructive Sleep Apnea
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 75 Years
Enrollment
555 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Jul 21, 2026, 2:18 PM EDT
Completed Phase 2 Interventional Results available

Study Exploring the Effect of Crizanlizumab on Kidney Function in Patients With Chronic Kidney Disease Caused by Sickle Cell Disease

NCT04053764
View directory record Official record
Conditions
Sickle Cell Disease (SCD)
Interventions
Crizanlizuamb, Standard of Care
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
6
States / cities
Birmingham, Alabama • Chicago, Illinois • Baton Rouge, Louisiana + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Jul 21, 2026, 2:18 PM EDT
Terminated Not applicable Interventional Results available

Does Thiazolidinedione Therapy Improve Endothelial Function and Preserve Renal Function

NCT00586261
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Pioglitazone, Placebo, Nitroglycerin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 14, 2013 · Synced Jul 21, 2026, 2:18 PM EDT
Completed Phase 2 Interventional Results available

A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria

NCT01847092
View directory record Official record
Conditions
Chronic Kidney Disease, Type 2 Diabetes Mellitus
Interventions
AZD1722, Placebo
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
18 Years to 80 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 26, 2020 · Synced Jul 21, 2026, 2:18 PM EDT
Completed Phase 2 Interventional

A Study to Learn About How Well BAY3283142 Works and Its Safety in Participants With Chronic Kidney Disease

NCT06522997
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
BAY3283142, Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1,222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
24
States / cities
Huntsville, Alabama • Chula Vista, California • San Dimas, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jul 21, 2026, 2:18 PM EDT
Completed No phase listed Observational

World Trade Center (WTC) RENAL

NCT02246101
View directory record Official record
Conditions
Cardiac Disease, Cardiopulmonary Disease, Renal Disease, Cardiovascular Disease
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
40 Years and older
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Jul 21, 2026, 2:18 PM EDT
Completed Not applicable Interventional Results available

Five, Plus Nuts and Beans for Kidneys

NCT03299816
View directory record Official record
Conditions
Chronic Kidney Disease, Hypertension
Interventions
Coaching DASH group (C-DASH), Self-Shopping DASH group (S-DASH)
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 100 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Jul 21, 2026, 2:18 PM EDT
Completed Phase 4 Interventional

Adrenocorticotropic Hormone (ACTH) Treatment of Nephrotic Range Proteinuria in Diabetic Nephropathy (NRDN)

NCT01028287
View directory record Official record
Conditions
Diabetic Nephropathy, Nephrotic Syndrome
Interventions
ACTH
Drug
Lead sponsor
Southeast Renal Research Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Jul 21, 2026, 2:18 PM EDT
Completed Phase 4 Interventional

Irbesartan Versus Placebo in Combination With Ramipril for Treatment of Albuminuria

NCT00095290
View directory record Official record
Conditions
Albuminuria
Interventions
Ramipril + Irbesartan, Ramipril + Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
55 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
11
States / cities
Tustin, California • Miami, Florida • West Palm Beach, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2011 · Synced Jul 21, 2026, 2:18 PM EDT
Completed Phase 2 Interventional Results available

Vascular Effects of Mineralocorticoid Receptor Antagonism in Kidney Disease

NCT02497300
View directory record Official record
Conditions
Chronic Kidney Disease, Albuminuria
Interventions
Spironolactone, Amiloride
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Jul 21, 2026, 2:18 PM EDT